SCHEMBL3870477

SCHEMBL3870477

NC(=O)c1cccc(O)c1-c1ccccc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.61
ALDH1A1 P00352 3/20 0.61
HPGD P15428 2/20 0.61
MAPT P10636 1/20 0.61
TSHR P16473 1/20 0.61
HSD17B10 Q99714 1/20 0.61
BCAT2 O15382 1/20 0.55
KEAP1 Q14145 1/20 0.49
NFE2L2 Q16236 1/20 0.49
HNF4A P41235 1/20 0.47
CA12 O43570 1/20 0.47
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
HMGB1 P09429 1/20 0.47
CA4 P22748 1/20 0.47
CA6 P23280 1/20 0.47
CA7 P43166 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
CA9 Q16790 1/20 0.47
NAPRT Q6XQN6 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27214460 0.88 BCAT2 (0.63) KDM4EALDH1A1HPGDMAPTTSHR
SCHEMBL27704997 0.84 BCAT2 (0.59) KDM4EALDH1A1HPGDMAPTTSHR
SCHEMBL623796 0.84 ALDH1A1 (0.61) KDM4EALDH1A1HPGDMAPTHSD17B10
SCHEMBL4151580 0.81 BCAT2 (0.59) KDM4EALDH1A1HPGDMAPTTSHR
SCHEMBL407835 0.81 BCAT2 (0.55) KDM4EALDH1A1HPGDMAPTTSHR
SCHEMBL2025737 0.81 BCAT2 (0.71) KDM4EALDH1A1HPGDMAPTTSHR
SCHEMBL530286 0.81 FABP4 (0.57) KDM4EALDH1A1HPGDMAPTTSHR
SCHEMBL29712321 0.81 BCAT2 (0.55) KDM4EALDH1A1HPGDMAPTTSHR
SCHEMBL16914158 0.81 ALDH1A1 (0.61) KDM4EALDH1A1HPGDMAPTTSHR
Propionamide SCHEMBL28350452 0.80 HNF4A (0.47) KDM4EALDH1A1HPGDMAPTTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1915337-A4 HYDROXYBENZAMIDE DERIVATIVES, THE METHOD FOR PREPARING THEREOF AND THE COSMETIC COMPOSITION CONTAINING THE SAME AMOREPACIFIC CORP (KR) 2009-04-22 EP claimed
US-20080280989-A1 Hydroxybenzamide Derivatives, the Method For Preparing Thereof and the Cosmetic Composition Containing the Same AMOREPACIFIC CORPORATION (KR) 2008-11-13 US claimed
CN-101243042-A Hydroxybenzamide derivatives, the method for preparing thereof and the cosmetic composition containing the same AMOREPACIFIC CORP (KR) 2008-08-13 CN claimed
EP-1915337-A1 HYDROXYBENZAMIDE DERIVATIVES, THE METHOD FOR PREPARING THEREOF AND THE COSMETIC COMPOSITION CONTAINING THE SAME Amorepacific Corporation (KR) 2008-04-30 EP claimed
WO-2007021067-A1 HYDROXYBENZAMIDE DERIVATIVES, THE METHOD FOR PREPARING THEREOF AND THE COSMETIC COMPOSITION CONTAINING THE SAME AMOREPACIFIC CORPORATION (KR) 2007-02-22 WO claimed
EP-1915337-A4 HYDROXYBENZAMIDE DERIVATIVES, THE METHOD FOR PREPARING THEREOF AND THE COSMETIC COMPOSITION CONTAINING THE SAME AMOREPACIFIC CORP (KR) 2009-04-22 EP disclosed
US-20080280989-A1 Hydroxybenzamide Derivatives, the Method For Preparing Thereof and the Cosmetic Composition Containing the Same AMOREPACIFIC CORPORATION (KR) 2008-11-13 US disclosed
CN-101243042-A Hydroxybenzamide derivatives, the method for preparing thereof and the cosmetic composition containing the same AMOREPACIFIC CORP (KR) 2008-08-13 CN disclosed
EP-1915337-A1 HYDROXYBENZAMIDE DERIVATIVES, THE METHOD FOR PREPARING THEREOF AND THE COSMETIC COMPOSITION CONTAINING THE SAME Amorepacific Corporation (KR) 2008-04-30 EP disclosed
WO-2007021067-A1 HYDROXYBENZAMIDE DERIVATIVES, THE METHOD FOR PREPARING THEREOF AND THE COSMETIC COMPOSITION CONTAINING THE SAME AMOREPACIFIC CORPORATION (KR) 2007-02-22 WO disclosed
CN-1355697-A IL-8 receptor antagonists SMITHKLINE BEECHAM CORP (US) 2002-06-26 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080280989-A1 Hydroxybenzamide Derivatives, the Method For Preparing Thereof and the Cosmetic Composition Containing the Same H1-0, HAAO, H1-10 KDM4E 621/4885ALDH1A1 96/4885HPGD 188/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.